← Back to Search

Sphingosine 1-phosphate receptor modulator

Oral Etrasimod for Crohn's Disease (CULTIVATE Trial)

Phase 3
Recruiting
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men or women 18 to 80 years of age
Ability to provide written informed consent or assent and to be compliant with the schedule of protocol assessments
Must not have
Have an ileostomy or a colostomy
Have functional or post-operative short-bowel syndrome or any associated complications that may require surgery or interfere with efficacy assessments
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 70 weeks for substudy a,approximately 24 weeks for substudy 1 and 2; 42 weeks for substudy 3; and 212 weeks for substudy 4
Awards & highlights
Pivotal Trial

Summary

This trial is testing a new oral medication called etrasimod for adults with severe Crohn's disease who haven't had success with other treatments. The medication aims to reduce gut inflammation by calming the immune system. The study will last several years and includes different stages to determine the best dosage and long-term effects. Etrasimod is also being tested for ulcerative colitis and may avoid issues that can lead to treatment failure with other therapies.

Who is the study for?
Adults aged 18-80 with moderate to severe Crohn's Disease, who haven't responded well to or can't tolerate steroids, immunosuppressants, or biologics. They must be able to follow the study plan and use contraception if they can have children.
What is being tested?
The trial is testing Etrasimod, an oral medication for Crohn's Disease. It compares Etrasimod against a placebo over several years to check its effectiveness and safety in those not helped by standard treatments.
What are the potential side effects?
Possible side effects of Etrasimod include headache, nausea, respiratory infections, high blood pressure, and potential impacts on liver function. The exact side effects will be monitored throughout the trial.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 80 years old.
Select...
I have been diagnosed with Crohn's disease for at least 3 months.
Select...
My Crohn's disease is currently moderate to severe.
Select...
I have Crohn's disease and treatments like steroids, immunosuppressants, or biologics didn’t work for me.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
You have a surgical opening in your abdomen to help eliminate waste.
Select...
I have short-bowel syndrome that might need surgery or affect treatment results.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 70 weeks for substudy a,approximately 24 weeks for substudy 1 and 2; 42 weeks for substudy 3; and 212 weeks for substudy 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 70 weeks for substudy a,approximately 24 weeks for substudy 1 and 2; 42 weeks for substudy 3; and 212 weeks for substudy 4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Number and Severity of Adverse Events

Side effects data

From 2022 Phase 3 trial • 42 Patients • NCT04706793
14%
Headache
11%
Malaise
11%
Pyrexia
7%
Colitis ulcerative
7%
Vaccination site pain
4%
Back pain
4%
COVID-19
4%
Contusion
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo Comparator: Placebo
Experimental: Etrasimod 2 mg

Awards & Highlights

Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Etrasimod Dose BExperimental Treatment1 Intervention
Group II: Etrasimod Dose AExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Etrasimod
2020
Completed Phase 3
~1580

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for Crohn's Disease include corticosteroids, immunosuppressants, biologics, and newer agents like Etrasimod. Corticosteroids reduce inflammation by suppressing the immune response, providing rapid relief of symptoms. Immunosuppressants such as thiopurines and methotrexate inhibit the proliferation of immune cells, helping to maintain remission. Biologics, including anti-TNF agents, target specific molecules involved in the inflammatory process, offering targeted therapy for moderate to severe cases. Etrasimod, a selective sphingosine 1-phosphate (S1P) receptor modulator, works by preventing lymphocytes from migrating to the gut, thereby reducing inflammation. Understanding these mechanisms is crucial for Crohn's Disease patients as it helps tailor treatment plans to effectively manage symptoms and maintain long-term remission.
Fostering Inflammatory Bowel Disease: Sphingolipid Strategies to Join Forces.

Find a Location

Who is running the clinical trial?

Arena is a wholly owned subsidiary of PfizerUNKNOWN
10 Previous Clinical Trials
1,396 Total Patients Enrolled
PfizerLead Sponsor
4,669 Previous Clinical Trials
17,860,749 Total Patients Enrolled
Arena PharmaceuticalsLead Sponsor
28 Previous Clinical Trials
4,627 Total Patients Enrolled

Media Library

Etrasimod (Sphingosine 1-phosphate receptor modulator) Clinical Trial Eligibility Overview. Trial Name: NCT04173273 — Phase 3
Crohn's Disease Research Study Groups: Etrasimod Dose A, Placebo, Etrasimod Dose B
Crohn's Disease Clinical Trial 2023: Etrasimod Highlights & Side Effects. Trial Name: NCT04173273 — Phase 3
Etrasimod (Sphingosine 1-phosphate receptor modulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04173273 — Phase 3
~125 spots leftby Jul 2025